Macugen v léčbě vlhké formy VPMD, první zkušenosti
| Title in English | Macugen in treatment of wet form of AMD, first experience |
|---|---|
| Authors | |
| Year of publication | 2007 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | This work assesses the results of applying the first selective antagonist of VEGF Macugen (pegaptanib) for subfoveal choroidal neovascular membrane (CNV) in age-related macular degeneration (ARMD). Macugen is a modified oligonucleotide that binds specifically to the extracellular VEGF165. Study included patients treated at our institution with Macugen for wet AMD in 2007. |